Exhibit 99.1 Ainos Reports First Quarter 2024 Financial Results Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024 US$9M growth capital secured in May strengthens financial position for executing growth strategy SAN DIEGO, May 13, 2024 /Accesswire/ — Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing ("POCT"), low-dose interferon therapeutics, and synthetic RNA-driven pre ...

Stock Performance - Ainos (NASDAQ:AIMD) stock is experiencing a significant surge with over 7 million shares traded, far exceeding its daily average trading volume of 978,000 shares [1] - The stock has shown volatility throughout the week, with today's movement appearing to be a continuation of earlier rallies [1] - AIMD stock is up 153 4% as of Friday morning but is down 41 7% year-to-date [2] Company Overview - AIMD's prior closing price was $1 12 per share, with a market capitalization of $5 239 million, classifying it as a penny stock [2] - The stock's float is approximately 1 08 million units, making it susceptible to manipulation and potential short squeezes [2] Market Context - The surge in AIMD stock occurs without any clear news or press releases from the company, indicating speculative trading activity [1] - Penny stocks like AIMD are often targeted by retail and day traders, increasing the risk of market manipulation [2]

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2023 Securities registered under Section 12(b) of the Exchange Act. | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | | | The Nasdaq Stock Market LLC | | Common Stock | AIMD | (Nasdaq Capital Market) | | | | The Nasdaq Stock Market LLC | | Common Stock ...

EX-99.1 2 aimd_ex991.htm PRESS RELEASE EXHIBIT 99.1 Ainos Reports Full Year 2023 Financial Results Strategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024 Advancing VELDONA drug candidates to Phase III clinical studies Expanding market of AI Nose-powered VOC-sensing technology with strategic partners NISD and Inabata SAN DIEGO, March 8, 2024 /Accesswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the developm ...

Stock Movement and Trading Activity - Ainos (NASDAQ:AIMD) stock experienced heavy trading with over 7 million shares traded in pre-market, significantly higher than its daily average of 637,000 shares [1] - The stock saw a 57.1% increase as of Monday morning, despite closing Friday down 45.3% year-to-date [2] - On Friday, the stock exhibited unusual trading activity with 4.2 million shares traded, despite a float of only 1.08 million units [2] Company Background and Market Position - Ainos is classified as a penny stock, with a prior closing price of $1.05 per share and a market capitalization of $4.912 million [1] - The company has not released any press statements, SEC filings, or new analyst coverage to explain the recent stock movement [1] Market Context and Investor Considerations - Penny stocks like AIMD are susceptible to manipulation due to their low entry point and market capitalization [2] - The stock's low float and high trading volume suggest potential volatility and speculative trading activity [2]

SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that Jack Lu, the Company's Director of Corporate Development, will present live at the Small-Cap Growth Virtual Investor Conference, hosted by VirtualInvestorConferences.com, on February 7, 2024. DATE: February 7 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _____________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File No. 0-20791 _____________________________________________ AINOS, IN ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____to____ Commission File No. 0-20791 AINOS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____to____ Commission File No. 0-20791 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 75-1974352 (State or other jurisdiction of (IRS ...

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 [Fee Required] For the Fiscal Year Ended December 31, 2022 ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 [No Fee Required] Commission File Number 0-20791 AINOS, INC. (Exact name of registrant as specified in its charter) | Texas | 75-1974352 | | --- | --- | | (State or other jurisdiction of incorporation or orga ...